trending Market Intelligence /marketintelligence/en/news-insights/trending/6jd405fs1727rla-88zv7a2 content esgSubNav
In This List

Insmed files application with US FDA for lung disease therapy

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Insmed files application with US FDA for lung disease therapy

Insmed Inc. a submitted a new drug application to the U.S. Food and Drug Administration for its lung disease treatment amikacin liposome inhalation suspension, or ALIS.

ALIS is aimed at treating adult patients with nontuberculous mycobacterial lung disease, a rare infection that can damage the lungs. The disease is caused by mycobacterium avium complex, a type of bacteria that affects people whose immune system is weak.

The application for the inhaled, once-daily formulation, is based on a successful phase 3 study, in which adding ALIS to standard treatment reduced bacterial density in 29% of the 336 adult patients enrolled.

Insmed expects to receive a six-month priority review from the U.S. FDA for ALIS.